先天性プロテインC欠乏症患者を対象とした凍結乾燥ヒトプロテインC濃縮物（TAK-662）の研究
基本情報
- NCT ID
- NCT06590974
- ステータス
- 募集中
- 試験のフェーズ
- -
- 試験タイプ
- 観察
- 目標被験者数
- 7
- 治験依頼者名
- Takeda
概要
This study is conducted in Japan of Freeze-dried Human Protein C Concentrate (TAK-662) used to treat participants with congenital protein C deficiency. The main aim of the study is to evaluate for adverse events and effectiveness of congenital protein C deficiency (TAK-662). During the study, participants with congenital protein C deficiency will be administered with TAK-662 intravenous injection in under routine normal practice. The investigators will evaluate adverse events due to TAK-662 for 12 months. For participants who will be administered in long-term supplementation of TAK-662 after acute treatment or short-term supplementation, the investigator will evaluate for 24 months as a maximum. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.